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The formation of acquired drug resistance is a major reason for the failure of anti-cancer
therapies after initial response. Here, we introduce a novel model of acquired oxaliplatin
resistance, a sub-line of the non-MYCN-amplified neuroblastoma cell line SK-N-AS that was
adapted to growth in the presence of 4000 ng/mL oxaliplatin (SK-N-ASrOXALI4000). SK-N-
ASrOXALI4000 cells displayed enhanced chromosomal aberrations compared to SK-N-AS,
as indicated by 24-chromosome fluorescence in situ hybridisation. Moreover, SK-N-ASrOX-
ALI4000 cells were resistant not only to oxaliplatin but also to the two other commonly used
anti-cancer platinum agents cisplatin and carboplatin. SK-N-ASrOXALI4000 cells exhibited a
stable resistance phenotype that was not affected by culturing the cells for 10 weeks in the
absence of oxaliplatin. Interestingly, SK-N-ASrOXALI4000 cells showed no cross resistance
to gemcitabine and increased sensitivity to doxorubicin and UVC radiation, alternative treat-
ments that like platinum drugs target DNA integrity. Notably, UVC-induced DNA damage is
thought to be predominantly repaired by nucleotide excision repair and nucleotide excision
repair has been described as the main oxaliplatin-induced DNA damage repair system. SK-
N-ASrOXALI4000 cells were also more sensitive to lysis by influenza A virus, a candidate for
oncolytic therapy, than SK-N-AS cells. In conclusion, we introduce a novel oxaliplatin
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resistance model. The oxaliplatin resistance mechanisms in SK-N-ASrOXALI4000 cells
appear to be complex and not to directly depend on enhanced DNA repair capacity. Models
of oxaliplatin resistance are of particular relevance since research on platinum drugs has so
far predominantly focused on cisplatin and carboplatin.
Introduction
Despite continuous progress over past decades, the prognosis for cancer patients whose disease
cannot be controlled locally remains generally unsatisfactory. More than 90% of cancer-associ-
ated deaths occur in patients with metastatic disease and the five-year survival rates are below
20% for this group [1,2].
Effective systemic therapies are needed to improve treatment outcome. A major obstacle in
the development of such therapies is the occurrence of drug resistance. Cancer cell drug resis-
tance can be intrinsic, i.e. there is no initial therapy response in previously untreated patients,
or acquired, i.e. tumours initially respond to therapy but eventually become resistant resulting
in treatment failure [3]. Acquired resistance is a major problem in a wide range of cancer types
[3]. An improved understanding of the processes underlying resistance acquisition is needed
to develop improved therapies. Drug-adapted cancer cell lines are preclinical model systems
that are used to study resistance formation in cancer cells and that have been shown to reflect
clinical mechanisms of acquired resistance [4–9].
Neuroblastoma is the most frequent solid extracranial paediatric cancer entity. About half
of the patients are diagnosed with high-risk disease associated with overall survival rates below
50% despite myeloablative therapy and differentiation therapy using retinoids [10–12]. Resis-
tance acquisition is a major issue in high-risk neuroblastoma. About half of high-risk neuro-
blastoma patients will relapse after completion of initial therapy leaving them with survival
rates below 10% [11,12]. High-risk neuroblastoma disease can be further classified into
tumours with or without MYCN amplification that differ substantially in biology and therapy
response [10–15].
An initial study has suggested oxaliplatin to be active in neuroblastoma cell lines [16].
Although there is limited evidence on the clinical efficacy of oxaliplatin in neuroblastoma
patients, oxaliplatin has been shown to be associated with an acceptable safety profile and is
suggested to display activity in some studies [17–20]. Here, we introduce a novel sub-line of
the neuroblastoma cell line SK-N-AS with acquired resistance to oxaliplatin (SK-N-ASrOX-
ALI4000). SK-N-AS was established from a bone marrow metastasis of a 6 year old female
patient with non-MYCN-amplified neuroblastoma (www.atcc.org) [21].
Materials and methods
Cells
The non-MYCN-amplified neuroblastoma cell line SK-N-AS was obtained from ATCC
(Manassas, VA, US). The oxaliplatin-resistant SK-N-AS sub-line SK-N-ASrOXALI4000 adapted
to growth in the presence of oxaliplatin 4000 ng/mL was derived from the resistant cancer cell
line (RCCL) collection (www.kent.ac.uk/stms/cmp/RCCL/RCCLabout.html) and had been
established by previously described methods [22]. In addition, we used an SK-N-ASrOX-
ALI4000 sub-line that had been cultivated for at least 10 passages in the absence of oxaliplatin
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(SK-N-ASrOXALI4000(-)) as a control. The MYCN-amplified UKF-NB-3 neuroblastoma cell
line was established from bone marrow metastases of a stage IV neuroblastoma patient [23].
All cells were propagated in IMDM supplemented with 10% FBS, 100 IU/ml penicillin and
100 μg/ml streptomycin at 37˚C. Cells were routinely tested for mycoplasma contamination.
Authentication was performed by short tandem repeat (STR) profiling. DNA was isolated
using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany), and the STR analysis
was performed using the PowerPlex 16 System (Promega, Mannheim, Germany) according to
the manufacturers’ protocols.
Viability assay
Cell viability was tested by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) dye reduction assay after 120 h incubation modified as described previously [22].
Virus infection
1500 viable cells were incubated for 4 days in 96-well plates prior to infection with H1N1 strain
A/WSN/33 at the indicated multiplicities of infection (MOIs) as previously described previ-
ously [24]. After 48h of incubation at 37˚C / 5% CO2 cell viability was determined by MTT
assay.
24-chromosome fluorescence in situ hybridisation (FISH)
24-chromosome FISH was performed as described previously [25,26] using a protocol that
involved six spectrally distinct fluorochromes PlatinumBright: 405 (blue), 415 (light blue/
aqua), 495 (green), 547 (light red/orange), 590 (dark red), 647 (far red) plus the DAPI counter-
stain in a four-stage probing and re-probing strategy [25,26]. Kreatech Diagnostics synthesised
all probes for this protocol, including 18 centromeric targets and six unique sequence targets
for chromosomes 5, 13, 14, 19, 21 and 22 using their Universal Linkage Labelling System www.
kreatech.com/rest/products/repeat-freetm-poseidontm-fish-dna-probes/preimplantation-
genetic-screening/multistar-24-fish.html. Blastomere nuclei were fixed to glass slides using
standard protocols described previously [27]. Slides were washed in PBS (2 min) followed by
dehydration and air-drying using an ethanol series. Pepsin treatment followed (1 mg/ml pep-
sin in 0.01 M HCl, 20 min at 37˚C), then rinsing in distilled water and PBS, then a paraformal-
dehyde (1% in PBS) fixation at 4˚C for 10 min, then PBS and distilled water washes followed
by ethanol dehydration and air drying. Four probe combinations [25] dissolved in hybridisa-
tion mix (Kreatech) were pre-denatured at 72–73˚C for 10 min and pipetted on to the slide.
Co-denaturation of probe and target cells at 75˚C for 90 s (Thermobrite-StatSpin, Vysis/
Abbott) proceeded before hybridisation at 37˚C. The hybridisation period for the first three
rounds of hybridisation (centromeric probes) was 30 min, whereas for the final round was
overnight. Post-hybridisation washes were for 1 min 30 s in 0.7 × SSC, 0.3% Tween 20 at 72˚C
followed by a 2 min in 2× SSC at room temperature. Slides were mounted in Vectashield con-
taining 0.1 ng/μL of DAPI (Vector labs) before microscopy and image analysis. After analysis
and image capture, slides were washed in 2× SSC at room temperature to remove the coverslip
and then washed for 30 s in distilled water (72˚C) to remove the bound probe. An ethanol
series preceded air-drying before continuation to the next round of hybridisation. The proto-
col was the same for the second, third and final rounds with the following exceptions: The
overnight hybridisation time for the final round (previously mentioned), pepsin and parafor-
maldehyde treatment were only required for the first round; the post-hybridisation wash time
was reduced with every round from 90 s (first round of hybridisation) to 50–60 s (second
round) to 30 s (third and final rounds). Microscopy analysis was performed on an Olympus
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BX-61 epifluorescence microscope equipped with a cooled CCD camera (by Digital Scientific
—Hamamatsu Orca-ER C4742-80) using the appropriate filters. To enable analysis of the
fluorochromes for image acquisition two communicating filter wheels (Digital Scientific UK)
with the appropriate filters were used. The recommended filters by the probe manufacturers
can be found here: www.kreatech.com/rest/customer-service-support/technical-support/
fluorophores-and-filter-recommendation.html
A modified version of SmartCapture software (Digital Scientific UK) was used to capture
all images, and to display results from all four hybridisation rounds in the same image, Adobe
Photoshop was used.
Receptor tyrosine kinase phosphorylation array
The phosphorylation status of 49 receptor tyrosine kinases was determined using a commer-
cial kit (Proteome Profiler Human Phospho-RTK Array Kit, R&D Systems, Abingdon, UK)
following the manufacturer’s instructions. Spot sizes were examined visually and densitomet-
ric analysis was performed using ImageJ software (http://imagej.nih.gov/ij/).
Respirometry
Oxygen consumption of intact cells was determined using two chambered Oxygraph-2k high
resolution respirometer (Oroboros, Innsbruck, Austria) at 37˚C in response to modulators of
oxidative phosphorylation. Results were analysed using DatLab software (Oroboros, Inns-
bruck, Austria). Baseline respiratory activity was determined for 30 min. Then, 8 μg/mL oligo-
mycin (Sigma-Aldrich Company Ltd, Dorset, UK) was added for 10 min. Oligomycin inhibits
ATP synthase resulting in proton leak and, in turn, a leak of respiration. This was followed by
treatment with FCCP (Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone) (Sigma-
Aldrich Company Ltd, Dorset, UK) 10 μM. FCCP interferes with the proton gradient by
uncoupling the electron transport chain from the oxidative phosphorylation system resulting
in maximal capacity of the respiratory chain.
Cell sensitivity to Ultraviolet C (UVC)-induced DNA damage
Effects of ultraviolet C (UVC)-irradiation on cell viability were determined by MTT assay
120h post irradiation with a UVG-11 compact UV lamp (UVP, Upland, CA) at a wave length
of 254 nm. Doses were calculated with a UVX digital radiometer (UVP, Upland, CA). In addi-
tion, a colony formation assay was performed. 10,000 cells were transferred into 60 mm dishes
and incubated for 11 days. Colonies were fixed, stained using crystal violet solution, and
counted.
Statistics
Results are expressed as mean ± S.D. of at least three experiments. In general, comparisons
between two groups were performed using Student’s t-test. Three or more groups were com-
pared by ANOVA followed by the Student-Newman-Keuls test. The fraction of diploid cells in
the project cell lines were compared by χ2 test with subsequent Bonferroni correction. P values
lower than 0.05 were considered to be significant.
Results
Cell line authentication by STR analysis
Prior to the start of the project, the identity of SK-N-AS and SK-N-ASrOXALI4000 was con-
firmed by STR analysis (S1 Table).
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Cytogenetic cell line characterisation
Representative images of the cytogenetic cell line characterisation by 24-chromosome fluores-
cence in situ hybridisation (FISH) are presented in Fig 1. Aneuploidy was observed in all the
cell lines. However, the level of aneuploidy overall was lower for the parental SK-N-AS cells
(50% diploidy) than for the oxaliplatin-resistant SK-N-AS sub-line SK-N-ASrOXALI4000 (34%
diploidy) and for SK-N-ASrOXALI4000 cells that had been cultivated for at least 10 passages in
the absence of oxaliplatin (SK-N-ASrOXALI4000(-), 38% diploidy) (S2 Table). Statistical analysis
revealed significant differences in the fraction of diploid cells between SK-N-AS and SK-N-
ASrOXALI4000 as well as between SK-N-AS and SK-N-ASrOXALI4000(-) cells, but not between
SK-N-ASrOXALI4000 and SK-N-ASrOXALI4000(-) cells. Chromosome numbers ranged from
23–160 for SK-N-AS and SK-N-ASrOXALI4000(-) cells and from 23–178 in SK-N-ASrOX-
ALI4000 cells. The increase in chromosome number was caused by increases in specific chro-
mosomes not whole metaphase duplication. Chromosomes 18 and X were more likely to
remain diploid (50–59% and 72–95% diploidy observed respectively) versus other chromo-
somes that showed higher levels of variation (S2 Table).
Chromosomal rearrangement within the metaphases was also common for all cell lines
investigated (S3 Table). Single colour chromosome painting of chromosomes 1, 3, 4, 5, 6, 7, 8,
13, 14, 17, 18, 22 and X showed signals on multiple chromosomes in 66–100% of metaphases
analysed. Chromosomes 10, 11, 12, 15 and 21 displayed signal on a single chromosome for
SK-N-AS (70–94%), but signals on multiple chromosomes for SK-N-ASrOXALI4000 and
SK-N-ASrOXALI4000(-) cells (44–100%) (S3 Table). Fig 1 shows an example of whole chromo-
some painting from this study. In this example, SK-N-AS cells display two signals for the chro-
mosomes 2, 8, and 12 showing that they are diploid for these chromosomes (Fig 1A–1C). In
contrast, more than two signals (Fig 1D–1I) as well as partially labelled chromosomes (Fig 1E
and 1I) can be seen in SK-N-ASrOXALI4000 and SK-N-ASrOXALI4000(-) cells.
Fig 1. Representative fluorescence in situ hybridisation (FISH) images of chromosomes 2 (A, D and
G), 12 (B, E and H) and 8 (C, F and I) in SK-N-AS (A-C), SK-N-ASrOALI4000(-) (D-F), and SK-N-
ASrOXALI4000 (G-I) neuroblastoma cells. Scale bar represents 10μm.
doi:10.1371/journal.pone.0172140.g001
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Cross-resistance profiles of SK-N-AS and its sub-lines
Next, we determined the drug resistance profiles of SK-N-AS, SK-N-ASrOXALI4000, and
SK-N-ASrOXALI4000(-) to a range of anti-cancer agents. This included the frequently used plat-
inum drugs oxaliplatin, cisplatin, and carboplatin. In addition, we examined the effects of two
additional anti-cancer drugs that target DNA integrity. Doxorubicin is an anthracycline that
targets DNA integrity through DNA intercalation and topoisomerase II inhibition [28,29].
Gemcitabine is a nucleoside analogue that is intracellularly activated through phosphorylation
[30]. Gemcitabine triphosphate is incorporated by DNA polymerase into the DNA resulting in
chain termination after addition of one more nucleotide triphosphate (masked chain termina-
tion). In addition, gemcitabine diphosphate covalently binds to and inhibits ribonucleotide
reductase resulting in the reduction of cellular nucleotide triphosphate pools and inhibition of
deoxycytidylate deaminase that inactivates gemcitabine monophosphate. These events
increase gemcitabine phosphorylation and incorporation into DNA (gemcitabine self-potenti-
ation) [30].
The oxaliplatin IC50 of SK-N-AS
rOXALI4000 cells was increased by 834-fold compared to
SK-N-AS cells, the IC90 was increased by 774-fold (Fig 2). SK-N-AS
rOXALI4000(-) cells (that had
been cultivated for 10 weeks in the absence of oxaliplatin) displayed slightly decreased IC50 and
IC90 values compared to SK-N-AS
rOXALI4000 cells but remained highly oxaliplatin-resistant
(IC50 SK-N-AS
rOXALI4000(-)/ IC50 SK-N-AS = 487; IC90 SK-N-AS
rOXALI4000(-)/ IC90 SK-N-
AS = 509) indicating a stable oxaliplatin resistance phenotype that does not depend on the con-
tinuous presence of oxaliplatin (Fig 2). SK-N-ASrOXALI4000 and SK-N-ASrOXALI4000(-) cells
displayed similar cross-resistance to cisplatin and carboplatin. The resistance factors for cis-
platin and carboplatin were lower than for oxaliplatin (S4 Table).
In contrast to the cross-resistance profiles against platinum drugs, SK-N-ASrOXALI4000
and SK-N-ASrOXALI4000(-) cells displayed no cross-resistance to doxorubicin and gemcitabine
(Fig 2, S4 Table). Notably, SK-N-ASrOXALI4000 and SK-N-ASrOXALI4000(-) cells were more
sensitive to doxorubicin than SK-N-AS cells.
Differentiation therapy using retinoic acids is a common constituent of treatment protocols
for high-risk neuroblastoma patients [11,12]. SK-N-AS cells were previously reported to be
insensitive to all-trans retinoic acid (ATRA)-induced differentiation [31]. In concordance, nei-
ther SK-N-AS cells nor SK-N-ASrOXALI4000 or SK-N-ASrOXALI4000(-) cells were sensitive to
ATRA in concentration of up to 5μM after treatment for up to five days.
Influenza A viruses are under investigation as oncolytic viruses [32–36]. To determine the
permissiveness of the investigated cell lines to influenza A virus infection, they were infected
with the H1N1 strain A/WSN/33 at different multiplicities of infection (MOIs). Cell viability
was determined at 48h post infection by MTT assay. Influenza A virus infection did not result
in a significant reduction of SK-N-AS cell viability at the investigated MOIs up to 3 (Fig 3). In
contrast, influenza A virus infection significantly reduced SK-N-ASrOXALI4000 cell viability at
MOIs ranging 1 and 3 and SK-N-ASrOXALI4000(-) viability at MOI 3. Notably, MYCN-ampli-
fied UKF-NB-3 cells were found to be substantially more sensitive to influenza A virus-
induced anti-cancer effects than MYCN-non-amplified SK-N-AS cells (Fig 3).
Receptor tyrosine kinase phosphorylation
49 receptor tyrosine kinases were analysed for their phosphorylation status (indicating kinase
activation) in the project cell lines using a commercial kit (Proteome Profiler Human Phos-
pho-RTK Array Kit, Abingdon, UK). Phosphorylation status was determined visually and den-
sitometrically using ImageJ software. Receptor tyrosine kinases were scored as phosphorylated
when spots were visible and the fold change spot density/ density control membrane was
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Fig 2. Effects of cytotoxic drugs on the viability of SK-N-AS cells, SK-N-AS cells with acquired
resistance to oxaliplatin (SK-N-ASrOXALI4000), or SK-N-ASrOXALI4000 cells that had been cultivated
for 10 weeks in the absence of oxaliplatin (SK-N-ASrOXALI4000(-)). Drug concentrations that reduce cell
viability by 50% (IC50) or 90% (IC90) were determined by MTT assay after 120h of incubation. * P < 0.05
relative to control; # mean ± S.D. (presented when no bar is visible on the chosen scale).
doi:10.1371/journal.pone.0172140.g002
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greater than 2.5. Eight receptor tyrosine kinases were phosphorylated in at least one cell line:
EGFR, INSR, IGF1R, PDGFRB, AXL, EPHA10, DDR2, and RYK (Fig 4A, S1 Fig). DDR2 and
EPHA10 phosphorylation was found > 2-fold reduced in SK-N-ASrOXALI4000 cells vs.
SK-N-AS cells but not in SK-N-ASrOXALI4000(-) cells vs. SK-N-AS cells suggesting that this
may be a consequence of the presence of oxaliplatin. PDGFRB and IGF1R displayed increased
phosphorylation in SK-N-ASrOXALI4000(-) cells vs. SK-N-AS cells but not in SK-N-ASrOX-
ALI4000 cells vs. SK-N-AS cells. INSR phosphorylation was > 2-fold enhanced in both SK-N-
ASrOXALI4000 cells and SK-N-ASrOXALI4000(-) cells compared to SK-N-AS cells (Fig 4B).
EGFR, AXL, and RYK displayed similar phosphorylation levels in all three cell lines as indi-
cated by fold changes of smaller than 2 (Fig 4B).
Cellular oxygen consumption
Respirometry experiments indicated that SK-N-AS and SK-N-ASrOXALI4000 cells display
functional oxidative phosphorylation and mitochondria. Oligomycin reduced oxygen con-
sumption and FCCP enhanced oxygen consumption (Fig 5). Hence, these cell lines do not
appear to display a Warburg metabolism. Since there were no significant differences between
the two cell lines, resistance formation to oxaliplatin does not appear to be associated with
changes in the cancer cell metabolism in this model.
Fig 3. Effects of H1N1 influenza A virus infection on cell viability. Non-MYCN-amplified SK-N-AS
neuroblastoma cells, SK-N-AS cells with acquired resistance to oxaliplatin (SK-N-ASrOXALI4000), SK-N-
ASrOXALI4000 cells that were passaged for 10 passages in absence of oxaliplatin (SK-N-ASrOXALI4000(-)), or
MYCN-amplified UKF-NB-3 neuroblastoma cells were infected with H1N1 influenza strain A/WSN/33 virus at
different multiplicities of infection (MOIs) and cell viability was determined 48h post infection relative to non-
treated control. The dotted line indicates the viability of non-infected control cells. * P < 0.05 relative to non-
infected control cells.
doi:10.1371/journal.pone.0172140.g003
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Fig 4. Phosphorylation status of 49 receptor tyrosine kinases. Receptor tyrosine kinase phosphorylation was determined by
a commercial kit (Proteome Profiler Human Phospho-RTK Array Kit, R&D Systems, Abingdon, UK) with subsequent
densitometric analysis using ImageJ software (http://imagej.nih.gov/ij/). A) Receptor tyrosine kinase phosphorylation status
expressed as fold change spot density relative to a control membrane area. Images of the membranes are presented in S1 Fig.
B) Differential phosphorylation of receptor tyrosine kinases that were found phosphorylated in at least one cell line (as indicated
by a fold change spot density relative to a control membrane area >2) in SK-N-ASrOXALI4000 or SK-N-ASrOXALI4000(-) cells
relative to SK-N-AS.
doi:10.1371/journal.pone.0172140.g004
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Cell sensitivity to ultraviolet C (UVC)-induced DNA damage
Nucleotide excision repair is assumed to be critically involved in the repair of platinum drug-
induced DNA damage and the nucleotide excision repair capacity has been suggested to deter-
mine cellular sensitivity to platinum drugs [37]. UVC also induces photoproducts that are
exclusively repaired by nucleotide excision repair [38]. Hence, we compared the UVC
response of SK-N-AS and SK-N-ASrOXALI4000 cells. Notably, SK-N-ASrOXALI4000 cells dem-
onstrated an increased UVC sensitivity compared to SK-N-AS at higher radiation doses as
indicated by MTT assay (Fig 6A). Similar results to those obtained for SK-N-ASrOXALI4000
cells were received for SK-N-ASrOXALI4000 cells (S2 Fig). This finding was confirmed by col-
ony formation assay (Fig 6B). These results do not suggest a contribution of increased nucleo-
tide excision repair as being relevant to the oxaliplatin resistance mechanism in SK-N-
ASrOXALI4000 cells.
Discussion
Here, we introduce SK-N-ASrOXALI4000, a sub-line of the non-MYCN-amplified neuroblas-
toma cell line SK-N-AS with acquired resistance to oxaliplatin. SK-N-ASrOXALI4000 cells dis-
played pronounced oxaliplatin resistance compared to parental SK-N-AS cells. Some studies
have reported that the formation of resistance to anti-cancer drugs may be the consequence of
a reversible enrichment of a pre-existing fraction of resistant cancer cells [39–41]. However,
SK-N-ASrOXALI4000 cells displayed a stable resistance phenotype that was maintained after a
cultivation period of 10 passages in the absence of oxaliplatin.
Cytogenetic cell line characterisation demonstrated that SK-N-ASrOXALI4000 cells acquired
additional chromosomal aberrations in addition to those observed in SK-N-AS cells as indi-
cated by increased levels of aneuploidy and chromosomal rearrangements. This may not be
unexpected given that platinum drugs including oxaliplatin are thought to exert their anti-can-
cer effects predominantly via causing DNA damage [42,43].
Previously, it was shown that a Warburg metabolism, i.e. the use of glycolysis for ATP pro-
duction instead of mitochondrial oxidative phosphorylation in the presence of sufficient oxy-
gen levels (aerobic glycolysis), may protect cancer cells from toxicity induced by platinum
drugs including oxaliplatin [44,45]. However, respirometry experiments indicated similarly
Fig 5. Oxygen consumption by SK-N-AS and SK-N-ASrOXALI4000 cells. Oxygen consumption was
determined in intact cells in the absence of treatment (baseline), in response to oligomycin (8 μg/mL), an
inhibitor of ATP synthase that causes a leak of protons resulting in inhibition of respiration (leak), and in
response to FCCP (10 μM) that uncouples the electron transport chain resulting in maximum oxidative
phosphorylation.
doi:10.1371/journal.pone.0172140.g005
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intact oxidative phosphorylation in both SK-N-AS and SK-N-ASrOXALI4000 cells indicating
no there was no metabolic shift towards a Warburg phenotype in oxaliplatin resistance.
Of the 49 receptor kinases examined, five kinases were found to be differentially phosphor-
ylated between the parental SK-N-AS cell line and its oxaliplatin-resistant sub-line. DDR2 and
EPHA10 phosphorylation were found to be reduced in SK-N-ASrOXALI4000 cells vs. SK-N-AS
cells but not in SK-N-ASrOXALI4000(-) cells vs. SK-N-AS cells. This suggests that these changes
may be a consequence of the continuous presence of oxaliplatin during cell cultivation in
SK-N-ASrOXALI4000 cells, rather than a sustainable resistance mechanism. Little is known
about a role of DDR2 or EPHA10 in the cellular response to platinum drugs. DDR2 is an extra-
cellular matrix receptor that may contribute to oncogenic processes, in particular through
Fig 6. Effects of ultraviolet C (UVC) radiation on the viability of SK-N-AS and SK-N-ASrOXALI4000 cells. A) Dose-dependent effects of UVC on
SK-N-AS and SK-N-ASrOXALI4000 cells as indicated by MTT assay five days post exposure. B) Representative images and quantification of colony
formation by SK-N-AS and SK-N-ASrOXALI4000 cells, as determined 11 days post exposure to UVC (32 J/m2) relative to non-irradiated control.
doi:10.1371/journal.pone.0172140.g006
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interaction with collagen [46]. EPHA10 is recognised as potential therapeutic target in breast
cancer [47], but its functional role remains to be characterised.
PDGFRB and IGF1R displayed increased phosphorylation in SK-N-ASrOXALI4000(-) cells
vs. SK-N-AS cells but not in SK-N-ASrOXALI4000 cells vs. SK-N-AS cells. Although PDGFRB
and IGF1R are well known anti-cancer drug targets previously shown to be involved in plati-
num drug resistance [48,49], it remains unclear how increased phosphorylation, which was
exclusively observed in oxaliplatin-resistant cells that had been cultivated in the absence of
oxaliplatin, may specifically contribute to oxaliplatin resistance in SK-N-ASrOXALI4000 cells.
Interestingly, cisplatin has been described to reduce PDGFRB expression in neuroblastoma
cells [50]. Hence, the difference between the PDGFRB levels in SK-N-ASrOXALI4000 and
SK-N-ASrOXALI4000(-) cells may be again the consequence of the presence of oxaliplatin dur-
ing the culturing of SK-N-ASrOXALI4000 cells.
INSR phosphorylation was consistently increased in both SK-N-ASrOXALI4000 cells and
SK-N-ASrOXALI4000(-) cells compared to SK-N-AS cells. This may suggest a role of INSR in
the context of acquired oxaliplatin resistance. However, INSR signalling has so far been associ-
ated with adverse events that have limited the clinical success of anti-cancer strategies targeting
IGF1R [51]. Therefore, the relevance of INSR phosphorylation remains unclear in the context
of acquired oxaliplatin resistance in our model.
Oxaliplatin belongs to the class of platinum-based anti-cancer drugs that target DNA integ-
rity through direct chemical interaction with DNA resulting in DNA strand breaks. In addi-
tion to oxaliplatin, cisplatin and carboplatin are platinum-based drugs that are frequently used
in cancer patients. Based on the analysis of drug-DNA adducts, the mechanisms of action of
cisplatin and carboplatin appear to be very similar while oxaliplatin differs in its mode of
action from these two compounds [42,43]. Moreover, oxaliplatin may offer a more favourable
toxicity profile compared to the other frequently used platinum-based anti-cancer agents, cis-
platin and carboplatin, and the cross-resistance profiles between oxaliplatin and cisplatin/ car-
boplatin may be incomplete [42,43,52–55]. In this context, SK-N-ASrOXALI4000 cells
displayed substantial cross-resistance to cisplatin and carboplatin although the oxaliplatin
resistance was much more pronounced.
Interestingly, SK-N-ASrOXALI4000 cells did not show cross-resistance to doxorubicin and
gemcitabine that induce DNA damage by alternative mechanisms [28–30]. While the gemcita-
bine sensitivity was similar in SK-N-AS and SK-N-ASrOXALI4000 cells, SK-N-ASrOXALI4000
cells were more sensitive to doxorubicin compared to SK-N-AS. The reasons for this increased
doxorubicin sensitivity remain unclear. Not much is known about the doxorubicin sensitivity
of platinum drug-adapted cancer cell line. However, cell line adaptation to platinum drugs
does not seem to be generally associated with increased doxorubicin sensitivity. A cisplatin-
resistant sub-line of the neuroblastoma cell line UKF-NB-3 displayed cross-resistance to doxo-
rubicin [56]. Among six cisplatin-adapted urothelial cancer cell lines, only one showed > 2-
fold increased sensitivity to doxorubicin compared to the respective parental cell line, while
the other five cell lines were similar sensitive to doxorubicin like the corresponding parental
cell lines [57].
SK-N-ASrOXALI4000 cells also displayed higher sensitivity to UVC irradiation than
SK-N-AS cells, although both UVC- and oxaliplatin-induced DNA damage are thought to be
predominantly repaired by nucleotide excision repair [38,58]. In this context, the nucleotide
excision repair capacity was suggested to determine cellular sensitivity to platinum drugs [37].
However, these findings may not be too surprising, given the well documented complexity of
the mechanisms that may underlie platinum drug resistance [58,59]. This involves mecha-
nisms that prevent platinum drug binding to DNA (pre-target resistance), mechanisms that
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inhibit cell death signalling downstream of DNA damage (post-target resistance), and/ or
mechanisms that do not have obvious links with the mechanism of action of platinum drugs
(off-target resistance) instead of, or in addition to, mechanisms that directly relate to platinum
drug-induced DNA damage [58,59].
Oncolytic viruses including influenza viruses are under preclinical investigation as anti-
cancer agents [32–36,60]. Virus-induced oncolytic effects have been described to be primar-
ily caused by virus replication associated with cancer cell lysis and cell death induction
[32,35,36,60]. Talimogene laherparepvec (T-VEC), an engineered herpes simplex virus-1,
was recently approved for the therapy of melanoma in the US and Europe. Interestingly,
SK-N-ASrOXALI4000 cells displayed increased sensitivity to influenza virus infection com-
pared to SK-N-AS cells. The reasons for this remain unclear. The activation of different
oncogenes has been described to promote virus replication in cancer cells [32,60], although
it is not clear whether this may be the mechanism in SK-N-ASrOXALI4000 cells. Neverthe-
less, this finding indicates that resistance acquisition to anti-cancer drugs may be associated
with a change in susceptibility to oncolytic viruses and that oncolytic viruses may represent
treatment options for cancer diseases after therapy failure even if the primary tumour was
not susceptible.
In conclusion, we introduce a novel oxaliplatin-resistant neuroblastoma cell line, SK-N-
ASrOXALI4000. The oxaliplatin resistance mechanisms appear to be complex and not be
directly associated to enhanced DNA repair capacity. Follow-up studies using methods includ-
ing transcriptomics and genomics analyses will be needed to elucidate the resistance mecha-
nisms in more detail. Models of oxaliplatin resistance are of particular relevance since research
on platinum drugs has so far vastly been focused on cisplatin (62,748 hits in PubMed, www.
ncbi.nlm.nih.gov/pubmed) and carboplatin (14,705 hits in PubMed), which are believed to
share the same mechanism of action [42,43], in comparison to oxaliplatin (8360 hits in
PubMed, data retrieved on 30th November 2016).
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